Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, MAT

Cartessa Aesthetics releases Subnovii Plasma Technology to the US Marketplace


MELVILLE, N.Y., Dec. 4, 2019 /PRNewswire-PRWeb/ -- Cartessa Aesthetics, one of the fastest growing aesthetics companies today, has launched Subnovii Advanced Plasma Technology for U.S. dermatologists, plastic surgeons and licensed aesthetic providers. The newest addition to their breakthrough portfolio, Subnovii is the only plasma to employ LF technology ? low frequency plus a patented wavelength and power combination. Subnovii's highly controlled, low frequency emission means treatments are more precise and predictable and healing time is reduced.

Plasma, the latest trend in aesthetic treatments, takes advantage of the fine layer of ionized gas, or plasma, that exists along the surface of skin. Subnovii emits a voltaic arc which sublimates the skin and kick starts fibroblast activity to stimulate collagen, elastin and hyaluronic acid. Only Subnovii's internal control system ensures the emitted energy is always consistent and that the toughest areas are treated with unmatched precision. The device is ergonomically superior and crafted from lightweight materials used by NASA and Airbus.

"As the market for non-invasive procedures continues to dramatically increase, areas surrounding the eyes and mouth remain difficult to treat and for which, no consistent, durable, predictable treatment has taken a lead position" shared Cartessa CEO and Founder, Gabe Lubin. "We feel Subnovii advanced plasma technology will quickly become an invaluable tool to deliver the results the market demands."

Dermatologists and Plastic Surgeons across the US have applauded Subnovii's versatility:
"I have not found anything similar which can easily and precisely target lesions without leaving pigmentary or texture changes after treatment. It has become a staple in my practice." ? Philadelphia Dermatologist, Dr. Thomas Griffin Jr.

"Subnovii has been a great addition to our aesthetic practice. Its unique and patented LF technology creates reliable results and is especially impressive for skin around the eyes, lips and neck." ? Boca Raton Dermatologist, Dr. Jordana Herschthal

"Small areas can be treated in about 20 minutes, the results are fantastic, and you can carry it in your lab coat." ? Chatanooga Facial Plastic Surgeon, Dr. Carey Nease

The launch of Subnovii is aligned with Cartessa's mission to bring superior devices for both provider and patient at a reasonable price-of-entry for the practice. Aesthetic providers interested in adding Subnovii to their practice are encouraged to reach out to a Cartessa agent.

About Cartessa Aesthetics
Cartessa Aesthetics, LLC sources leading aesthetic medical devices for distribution to dermatologists, plastic surgeons, cosmetic physicians and medical spas. Cartessa selects the most cutting-edge technologies that offer clinically proven efficacy, patient safety, and the best possible investment for patients and professionals. For more information visit: http://www.cartessaaesthetics.com

 

SOURCE Cartessa Aesthetics


These press releases may also interest you

at 20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announce...

at 20:00
InterDent announces that most Oregon offices will remain open to maintain access to preventive services for Oregon communities. Capitol Dental Care will continue to partner with Oregon county organizations to provide support for communities affected...

at 19:05
FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human...

at 17:30
Aimee Daramus, Psy.D., clinical psychologist, has been quoted on topics related to mental illness in Bustle, HuffPost, wellandgood.com, Mic.com, and several other media outlets. On Sept. 15, 2020, Callisto Press released her first book, Understanding...

at 14:01
Eli Lilly and Company today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people...

at 12:35
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statistically significant and clinically meaningful improvement...



News published on 4 december 2019 at 08:00 and distributed by: